Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1075457,
author = {Malčíková, Jitka and Jurček, Tomáš and Rázga, Filip and Dvořáková, Dana and Žáčková, Daniela and Darzentas, Nikos and Šebejová, Ludmila and Šmardová, Jana and Oltová, Alexandra and Juračková, Lenka and Trbušek, Martin and Doubek, Michael and Pospíšilová, Šárka and Mayer, Jiří and Ráčil, Zdeněk},
booktitle = {17th Congress of the European Hematology Association, Amsterdam},
language = {eng},
title = {T315I mutations are clustered with advanced phases contrary to other aberrations in CML patients resistant to TKI therapy},
url = {http://www.haematologica.org/content/97/supplement_1/haematol_97_s1.full.pdf},
year = {2012}
}
TY - CONF
ID - 1075457
AU - Malčíková, Jitka - Jurček, Tomáš - Rázga, Filip - Dvořáková, Dana - Žáčková, Daniela - Darzentas, Nikos - Šebejová, Ludmila - Šmardová, Jana - Oltová, Alexandra - Juračková, Lenka - Trbušek, Martin - Doubek, Michael - Pospíšilová, Šárka - Mayer, Jiří - Ráčil, Zdeněk
PY - 2012
TI - T315I mutations are clustered with advanced phases contrary to other aberrations in CML patients resistant to TKI therapy
UR - http://www.haematologica.org/content/97/supplement_1/haematol_97_s1.full.pdf
N2 - Various mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in chronic myelogenous leukemia (CML) patients were described. Among them, mutations within BCR-ABL1 kinase domain are the most frequently studied, since they affect binding of TKI molecule. However, mechanisms leading to subsequent progression are still not fully elucidated. Inhibition of BCR-ABL1 by imatinib was suggested to induce p53 pathway, therefore, p53 inactivation could possibly influence therapy response. Beside this, mutations in genes involved in myeloid transformation (e.g. ASXL11 and CBL) were identified, and their role in disease progression is under investigation. Aims. We analyzed genomic aberrations and mutations in BCR-ABL1, TP53, ASXL1 and CBL genes in patients with primary or acquired resistance to TKIs therapy.
ER -
MALČÍKOVÁ, Jitka, Tomáš JURČEK, Filip RÁZGA, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Nikos DARZENTAS, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Michael DOUBEK, Šárka POSPÍŠILOVÁ, Jiří MAYER a Zdeněk RÁČIL. T315I mutations are clustered with advanced phases contrary to other aberrations in CML patients resistant to TKI therapy. In \textit{17th Congress of the European Hematology Association, Amsterdam}. 2012. ISSN~0390-6078.
|
